Coronary Heart Disease, Unstable Angina
Conditions
Brief summary
In this study, typical cases of coronary heart disease are selected. They will be intervened by Xuesaitong soft capsules to investigate efficacy and safety for Coronary Heart disease.
Interventions
Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.
DRUGPlacebo oral capsule
Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
Sponsors
Jie Wang
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of coronary angiography unstable angina * Clinical diagnosis of unstable angina * Age of 30 to 75 years old * Not use thrombolysis, dilate coronary drugs within two weeks * Sign the consent
Exclusion criteria
* Severe valvular heart disease * Insulin-dependent diabetes * mental disease * Combined with severe liver, kidney, hematopoietic system disorder * Patients with malignant tumors * Pregnancy or breast-feeding women * Recent history of trauma * Drug allergy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| major adverse cardiovascular events | 60 days | death, myocardial infarction, hospitalization for unstable angina or stroke |
| Seattle Angina Questionnaire | 60 days | to evaluate patients by Seattle Angina Questionnaire |
| blood stasis syndrome scale of Coronary heart disease angina pectoris | 60 | to evaluate patients by blood stasis syndrome scale of Coronary heart disease angina pectoris |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| lipid | 60 | Triacylglyceride,total cholesterol, low densith lipoprotein, high densith lipoprotein |
Countries
China
Contacts
Primary ContactLian Duan
Outcome results
None listed